# Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer

> **NCT01611558** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 40 (actual)

## Conditions studied

- Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line

## Interventions

- **BIOLOGICAL:** Ipilimumab

## Key facts

- **NCT ID:** NCT01611558
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-21
- **Primary completion:** 2014-11-03
- **Final completion:** 2019-07-03
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01611558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01611558, "Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01611558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*